Tenderwize
Wróć do wyszukiwania

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 431 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

5/100

Ocena szansy

High riskLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

5 / 100

Złożoność

30 / 100

Czynniki ryzyka

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Weak opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of drug discount agreements for the active substance Omalizumab under German social law (§130a Abs. 8 SGB V).
  • Open House procedure: no individual negotiations, uniform conditions, no exclusivity.
Pokaż pełne podsumowanie

This notice concerns an Open-House procedure (not a classic EU procurement) for discount agreements on the active substance Omalizumab, under §130a Abs. 8 SGB V. The lead buyer is Techniker Krankenkasse. The procedure was originally open until October 2027, but a change notice (XML) indicates the procedure was prematurely ended on 30 June 2026. No estimated value is provided. Only one lot exists. Eligibility requires pharmaceutical entrepreneur status with proper authorization. Award criteria are not specified (placeholder only). Documents were not analyzed. Due to the premature termination, this tender is effectively closed.

Ryzyka

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with a valid authorization for the offered medicinal product.
  • Sitz in Germany, another EU member state, or EEA state (§9 Abs. 2 Satz 1 AMG).

Eligibility

  • Declaration of eligibility and reliability (Anlage 4) to be signed in text form.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Conclusion of discount agreements for Omalizumab with all eligible pharmaceutical entrepreneurs. No exclusivity, fixed conditions. Max contract duration 24 months from 01.11.2025 to 31.10.2027.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Oct 2025 - Oct 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Termin

Deadline Oct 30, 2027

Szczegóły zamówienia

Data publikacji
20 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
347743-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3